Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.
Kato M, Okamoto Y, Imamura T, Kada A, Saito AM, Iijima-Yamashita Y, Deguchi T, Ohki K, Fukushima T, Anami K, Sanada M, Taki T, Hashii Y, Inukai T, Kiyokawa N, Kosaka Y, Yoshida N, Yuza Y, Yanagimachi M, Watanabe K, Sato A, Imai C, Taga T, Adachi S, Horibe K, Manabe A, Koh K. Kato M, et al. Among authors: iijima yamashita y. J Clin Oncol. 2024 Nov 12:JCO2400811. doi: 10.1200/JCO.24.00811. Online ahead of print. J Clin Oncol. 2024. PMID: 39531610
High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor.
Aoki T, Shiba N, Tsujimoto S, Yamato G, Hara Y, Kato S, Yoshida K, Ogawa S, Hayashi Y, Iwamoto S, Taki T, Shimada A, Iijima-Yamashita Y, Horibe K, Tawa A, Taga T, Adachi S, Tomizawa D. Aoki T, et al. Among authors: iijima yamashita y. Pediatr Blood Cancer. 2024 Feb;71(2):e30803. doi: 10.1002/pbc.30803. Epub 2023 Dec 6. Pediatr Blood Cancer. 2024. PMID: 38054691
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, Hasegawa D, Terui K, Hama A, Tsujimoto SI, Kiyokawa N, Miyachi H, Deguchi T, Hashii Y, Iijima-Yamashita Y, Taki T, Noguchi Y, Koike K, Koh K, Yuza Y, Moriya Saito A, Horibe K, Taga T, Tanaka S, Adachi S. Tomizawa D, et al. Among authors: iijima yamashita y. Leukemia. 2024 Jan;38(1):202-206. doi: 10.1038/s41375-023-02075-9. Epub 2023 Nov 6. Leukemia. 2024. PMID: 37926712 No abstract available.
Prognostic value of minimal disseminated disease assessed using digital polymerase chain reaction for 3'ALK assays in pediatric anaplastic lymphoma kinasepositive anaplastic large cell lymphoma.
Fukano R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, Saito AM, Takimoto T, Sekimizu M, Suehiro Y, Yamasaki T, Hasegawa S, Mori T, Horibe K. Fukano R, et al. Among authors: iijima yamashita y. Haematologica. 2024 Feb 1;109(2):652-656. doi: 10.3324/haematol.2023.282812. Haematologica. 2024. PMID: 37675509 Free PMC article. No abstract available.
Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia.
Miyagawa N, Goto H, Ogawa A, Kikuta A, Kosaka Y, Sekimizu M, Tomizawa D, Toyoda H, Hiramatsu H, Hara J, Mochizuki S, Nakayama H, Yoshimura K, Iijima-Yamashita Y, Sanada M, Ogawa C. Miyagawa N, et al. Among authors: iijima yamashita y. Int J Hematol. 2023 Aug;118(2):267-276. doi: 10.1007/s12185-023-03609-8. Epub 2023 May 1. Int J Hematol. 2023. PMID: 37127801 Clinical Trial.
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S. Makishima H, et al. Among authors: iijima yamashita y. Blood. 2023 Feb 2;141(5):534-549. doi: 10.1182/blood.2022018221. Blood. 2023. PMID: 36322930 Free PMC article.
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Yamada Y, Osumi T, Kato M, Shioda Y, Kiyotani C, Terashima K, Hayakawa A, Iijima-Yamashita Y, Horibe K, Matsumoto K, Tomizawa D. Yamada Y, et al. Among authors: iijima yamashita y. J Pediatr Hematol Oncol. 2022 May 1;44(4):178-180. doi: 10.1097/MPH.0000000000002404. Epub 2022 Jan 28. J Pediatr Hematol Oncol. 2022. PMID: 35091516
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. Yasuda T, et al. Among authors: iijima yamashita y. Blood. 2022 Mar 24;139(12):1850-1862. doi: 10.1182/blood.2021011921. Blood. 2022. PMID: 34695176 Free article.
20 results